Chinese startups Cure Genetics and Frametact ink $60 M deal to develop gene therapy for familial neurological diseases

China-based startup Cure Genetics and Frametact, founded by a molecular neuroscience research team at The Hong Kong University of Science and Technology and Hong Kong Center For Neurodegenerative Diseases, have jointly announce the signing of a collaborative development and licensing agreement.

The partnership will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases.

According to the agreement, Cure Genetics will receive an upfront and milestone payment totaling $60 million. Additionally, upon the market launch of the product, Cure Genetics will continue to receive sales royalties based on net revenue.

This collaboration will leverage the extensive expertise of Frametact in the domain of neurological diseases, combined with Cure Genetics' leading technology in AAV vector development and efficient in vivo AAV screening. Together, the companies will work on developing treatments for familial neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease.

This collaboration, following a previous partnership with Boehringer Ingelheim, marks another significant step forward for Cure Genetics with a globally leading organisation. It not only validates the global advancement of the VELP™ platform but also signifies a leap forward in Cure Genetics' internationalisation process. 

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!